Matthew A. Spear - 01 Mar 2022 Form 4 Insider Report for Poseida Therapeutics, Inc.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 01 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Mar 2022, 18:28:00 UTC
Prior SEC filing: 08 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Harry J. Leonhardt, Attorney-in-Fact

Key filing fact

Matthew A. Spear filed Form 4 for Poseida Therapeutics, Inc. on 01 Mar 2022.

Key facts

This page summarizes Matthew A. Spear's Form 4 filing for Poseida Therapeutics, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Mar 2022, 18:28.

Change

Previous filing in this sequence was filed on 08 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PSTX transaction

Common Stock

Award

Transaction value: $0
Shares: +50,000
Change %: +81%
Price: $0.000000
Shares after: 111,485
Date: 01 Mar 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PSTX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +72,568
Change %
Price: $0.000000
Shares after: 72,568
Date: 01 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 72,568
Exercise price: $3.42
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.

Footnote F2

12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.